Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab for hidradenitis suppurativa – mode of action study
2018-002978-52Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of guselkumab in hidradenitis suppurativa (HS), sponsored by University Medical Center Groningen. Primary endpoint: Expression levels of inflammatory cytokines in HS lesional skin. Started Jun 2019; status: active.
02
Drugs
guselkumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2018-002978-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002978-52.